Stock SILK SILK ROAD MEDICAL, INC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Silk Road Medical, Inc

Equities

SILK

US82710M1009

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		5-day change 1st Jan Change
21.09 USD +1.79% Intraday chart for Silk Road Medical, Inc +2.58% +71.88%
04-30 Transcript : Silk Road Medical, Inc, Q1 2024 Earnings Call, Apr 30, 2024
04-30 Earnings Flash (SILK) SILK ROAD MEDICAL Reports Q1 Revenue $48.5M, vs. Street Est of $44.7M MT

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Sales forecast by analysts have been recently revised upwards.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • With an enterprise value anticipated at 4.08 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SILK ROAD MEDICAL, INC Stock Silk Road Medical, Inc
+71.88% 817M
C
ABBOTT LABORATORIES Stock Abbott Laboratories
-5.51% 182B
C+
MEDTRONIC PLC Stock Medtronic plc
+2.33% 111B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.62% 68.48B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.52% 49.69B
B-
CENCORA, INC. Stock Cencora, Inc.
+8.06% 44.46B
B-
HOYA CORPORATION Stock Hoya Corporation
+6.24% 40.67B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+23.35% 31.22B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+0.67% 26.09B
A-
TERUMO CORPORATION Stock Terumo Corporation
+18.43% 25.32B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SILK Stock
  4. Ratings Silk Road Medical, Inc